Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Zühlke Ventures has backed the medical device developer's series A round, which was led by Arboretum Ventures.

Kaiser Foundation Hospitals and Medpace took part in a round that will support phase 3 trials for the startup's lead cardiometabolic disease drug candidate.

The behavioural health assistance platform will get a public listing through the deal, which follows $110m from investors including SoftBank.

Illumina Ventures and AV8 Ventures returned for a series A round that will push the startup's liquid biopsy technology towards the clinical trial stage.

Lundbeck and Novo were among the participants in the immuno-oncology drug developer's series B round having backed its series A four years ago.

The Minth Group, Zoll Medical and Abiomed-backed medical device developer has raised at least $217m in total after closing additional series D funding.

The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.

Pfizer's Breakthrough Growth Initiative has backed the PureTech microbiome spinoff, which will use the cash to finance phase 2 tests of its lead IBD drug candidate.

The book publisher and nursing care service group’s Gakken Innovation-Tech Fund plans to invest about $29m over the next five years, targeting edtech and healthtech.